Compare PPSI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPSI | SKYE |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 44.9M |
| IPO Year | 2008 | 2013 |
| Metric | PPSI | SKYE |
|---|---|---|
| Price | $3.51 | $0.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $12.00 | ★ $14.75 |
| AVG Volume (30 Days) | 74.4K | ★ 303.6K |
| Earning Date | 01-01-0001 | 06-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1626.32 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,879,000.00 | N/A |
| Revenue This Year | $26.84 | N/A |
| Revenue Next Year | $10.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.26 | $0.65 |
| 52 Week High | $5.70 | $5.75 |
| Indicator | PPSI | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 42.86 | 40.77 |
| Support Level | $3.25 | N/A |
| Resistance Level | $4.05 | $0.83 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 33.02 | 11.47 |
Pioneer Power Solutions Inc designs, manufactures, integrates, services, and sells distributed energy resources, on-site and mobile power generation equipment, and a platform of mobile electric vehicle (EV) charging solutions.. Its principal products and services include custom-engineered electrical transformers, switchgear and engine-generator sets and controls, complemented by a national field-service network to maintain and repair power generation assets.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.